Signals, Powered By EquityPandit
Lupin Ltd has got a final approval from the USFDA for marketing sodium, potassium sulfate, magnesium sulfate oral solution that are used in treatment of a form of cancer.
Lupin has said in a BSE filing that “It has received final approval for its sodium sulfate, potassium sulfate, magnesium sulfate oral solution, 17.5 g/3.13 g/ 1.6 g per ounces from the United States Food and Drug Administration (FDA) to market a generic version of Braintree Laboratories’ Suprep Bowel Prep Kit.”
